Zacks Investment ResearchSep 10, 10:15 AM ET▼ Negative
Stock declined 2.7% post-earnings, significantly underperforming S&P 500's 0.5% gain. Sales and earnings both contracted substantially (6.7% and 44% respectively), with EBITDA declining 28.6%. While backlog increased slightly and International segment showed profitability gains, the overall deterioration in core Lab Products Group performance and extended project timelines amid economic uncertainty outweigh positive factors.
Also mentions KEQU
Articles that tag KEQU but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
